Please login to the form below

Not currently logged in
Email:
Password:

tedizolid phosphate

This page shows the latest tedizolid phosphate news and features for those working in and with pharma, biotech and healthcare.

Merck defeated in antibiotic patent case in US

Merck defeated in antibiotic patent case in US

In addition to Cubicin, buying Cubist has also given Merck Sivextro (tedizolid phosphate) - anther treatment for skin and skin structure infections, and Zerbaxa (ceftolozane/tazobactam) for complicated intra-abdominal and urinary

Latest news

  • Merck prepares filings for Clostridium antibody Merck prepares filings for Clostridium antibody

    Merck bolstered its anti-infectives pipeline last year with the $8.4bn acquisition of Cubist Pharmaceuticals, which added a range of antibiotics including recently-approved Sivextro (tedizolid phosphate) and Zerbaxa

  • Antibiotics among 7 new drugs backed by EMA Antibiotics among 7 new drugs backed by EMA

    Both The Medicines Company's Orbactiv (oritavancin) and Cubist's Sivextro (tedizolid phosphate) were among seven new medicines backed by EMA scientific advisers in the Committee for Medicinal Products for Human

  • FDA backs Cubist's antibiotic Zerbaxa FDA backs Cubist's antibiotic Zerbaxa

    The approval of Zerbaxa adds to Cubist's stable of antibiotics, which include $1bn-a-year blockbuster Cubicin (daptomycin) as well as recently-approved Sivextro (tedizolid phosphate) for acute bacterial skin

  • UPDATE: Merck to acquire Cubist for $8.4bn UPDATE: Merck to acquire Cubist for $8.4bn

    Cubicin is Cubist's leading product. The company's portfolio has been strengthened recently by the approval of Sivextro (tedizolid phosphate) to treat acute bacterial skin and skin structure infections, while

  • EMA accepts Cubist antibiotic for review EMA accepts Cubist antibiotic for review

    Cubist is one of the few companies still investing in the area and recently received FDA approval for another antibiotic - Sivextro (tedizolid phosphate) - for the treatment of acute bacterial skin and

More from news
Approximately 3 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Cubist: Meeting the challenge in antibiotics Cubist: Meeting the challenge in antibiotics

    For Cubist its beliefs have been justified with the approval of the new antibiotic Sivextro (tedizolid phosphate) to treat acute bacterial skin and skin structure infections, while another drug - ceftolozane/tazobactam - ... Cubist's pipeline. Phase I.

  • Pharma deals during December 2014 Pharma deals during December 2014

    Cubist's acquisition of Trius Therapeutics brought a late-stage antibiotic candidate, tedizolid phosphate, as well as several preclinical antibiotic programmes. ... Approved in 2014, tedizolid phosphate ( Sivextro) is for the treatment of adult acute

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    8, 600. Trius Therapeutics / Cubist Pharmaceuticals. Acquisition. Antibiotic pipeline inc TR-701 (tedizolid phosphate, p3).

  • Pharma deals during July 2013 Pharma deals during July 2013

    Dificid was launched in the US in July 2011. Trius' lead product is a phase III stage antibiotic, tedizolid phosphate (TR-701), being developed for the treatment of certain Gram-positive

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics